HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2015
- Investigational device exemption submitted to FDA, on track for first patient dosing in March in Phase 3 Study of metastatic pancreatic cancer patients -
- Growing momentum in ENHANZE™ franchise with recent signing of Lilly collaboration and first dosing in clinical trials with Janssen’s Daratumumab, AbbVie’s HUMIRA® and Pfizer’s Rivipansel and Bococizumab -
- Full year revenue of $135.1 million compared to $75.3 million in prior year, Royalty Revenue of $31 million increased 229 percent from prior year -
SAN DIEGO, February 29, 2016 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2015, which included a fourth quarter increase in royalty revenue of 136 percent from the prior year period and net income of $4.3 million, or $0.03 per share, compared to a net loss in the fourth quarter of 2014 of $5.3 million, or $0.04 per share. For the full year, total revenue increased 79 percent to $135.1 million compared to $75.3 million in the prior year.
“We closed 2015 with record progress across both pillars of our strategy and enter 2016 with strong momentum,” said Dr. Helen Torley, president and chief executive officer. “In our oncology pillar, an investigational device exemption was submitted to the FDA earlier this month by our partner Ventana for the PEGPH20 companion diagnostic test. We remain on track to dose the first patient in March in our Phase 3 study in pancreatic cancer patients. We are also continuing to evaluate the dose of PEGPH20 in our lung and gastric cancer trials and are preparing for the initiation of the breast cancer trial with our clinical partner Eisai.
“At the same time, our ENHANZE™ platform continues to generate more value than any other time in company history. With royalty revenue growth in the fourth quarter, a newly signed licensing and collaboration agreement with Eli Lilly and four co-formulated products in the clinic, our ENHANZE platform remains a clear differentiator in any market environment.”
The following information was filed by Halozyme Therapeutics Inc (HALO) on Monday, February 29, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Halozyme Therapeutics Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed, and by Halozyme Therapeutics Inc.
Ticker: HALO CIK: 1159036 Form Type: 10-K Annual Report Accession Number: 0001159036-16-000100 Submitted to the SEC: Mon Feb 29 2016 4:05:25 PM EST Accepted by the SEC: Mon Feb 29 2016 Period: Thursday, December 31, 2015 Industry: Biological Products No Disgnostic Substances